Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

5.9%

2 terminated/withdrawn out of 34 trials

Success Rate

92.6%

+6.1% vs industry average

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

36%

9 of 25 completed trials have results

Key Signals

2 recruiting9 with results

Enrollment Performance

Analytics

Phase 1
16(51.6%)
N/A
7(22.6%)
Phase 2
7(22.6%)
Phase 4
1(3.2%)
31Total
Phase 1(16)
N/A(7)
Phase 2(7)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (34)

Showing 20 of 34 trials
NCT05046158Not ApplicableCompleted

Diabetic Foot Ulcers-Comparing Transforming Powder to Standard of Care

Role: collaborator

NCT04182490Phase 2Completed

LMN-101 in a Campylobacter Human Challenge Model

Role: collaborator

NCT05933525Phase 2Completed

Clinical Study to Assess the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model

Role: collaborator

NCT06122870Phase 1Completed

CampETEC Hyperimmune Bovine Colostrum (HBC)

Role: collaborator

NCT04597437Phase 2Recruiting

Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)

Role: collaborator

NCT05959616Phase 1Recruiting

Shigella Sonnei 53G Human Infection Study in Kenyan Adults

Role: collaborator

NCT04953754Not ApplicableUnknown

Melatonin and Vaccine Response, Immunity, and Chronobiology Study

Role: collaborator

NCT04794621Not ApplicableCompleted

Electroceutical Dressing Technology (EDT) Against Wound Microbial Biofilm Infection

Role: collaborator

NCT01524822Completed

The Effects of Chronic Exposure to Low-Level Blasts

Role: collaborator

NCT02498301Not ApplicableCompleted

Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD

Role: collaborator

NCT05203744Phase 4Unknown

Escalating Monthly Doses of Tafenoquine in Healthy Volunteers

Role: lead

NCT00392015Phase 1Completed

NMRC-M3V-Ad-PfCA Vaccine - Clinical Trial 1

Role: collaborator

NCT03576183Phase 2Completed

Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701

Role: collaborator

NCT03404674Phase 1Completed

Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)

Role: collaborator

NCT04203186Not ApplicableWithdrawn

A Clinical Trial to Evaluate Plasmodium Falciparum 7G8 and NF54 Challenge Strains (PfSPZ) in a Head-to-head Comparative Study - (ECG-CHMI)

Role: collaborator

NCT03341754Phase 1Completed

Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults

Role: collaborator

NCT03040687Phase 1Completed

Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge

Role: collaborator

NCT03762070Unknown

Evaluation of a Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in Peru

Role: lead

NCT02280044Phase 2Completed

Efficacy of Rifaximin in Preventing Campylobacteriosis

Role: collaborator

NCT02601716Phase 2Completed

PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults

Role: collaborator